NR4A1 and ductal breast carcinoma in situ: Moreover, a case-series analysis at a single-center in South Korea found that adjuvant HT combining RT with BCS further reduced LR by 30% in 50 women with hormone receptor (HR)-positive (+) DCIS, which is regarded with a low risk of recurrence [9, 10].